원문정보
초록
영어
Asthma is one of the major public health problems worldwide and the morbidity and mortality of asthma has increased in the past two decades. To develop the botanical new drug for asthma, we discovered natural product that activated beta2-adrenergic receptor( 2AR) in the reporter assay. It also inhibited nuclear factor (NF)- B activation. Administration of the NDR10113 to ovalbumin (OVA)-induced asthmatic mice improved the airway hyperresponsiveness (AHR). Moreover, NDR10113 exhibited a decrease of serum IgE level and bronchial inflammation. Results from flow cytometric analysis (FACS) showed the absolute number of total cells in the lung-draining mediastinal lymph nodes (MLN) were significantly suppressed by NDR10113
administration, and also that absolute numbers of CD3+ T cells, CD4+ Th cells, and B220+ B cells reduced. Furthermore, the lung tissue of NDR10113 treatment group showed much less eosinophils, bloods, and collagen accumulating compared with that of OVA-induced
control group. Taken together, these results suggest NDR10113 might be beneficial for the treatment of asthma.